drugset
drugset / Trial / NCT03198182

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

NCT03198182 ↗

Phase 1 Completed 63 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate safety, and tolerability of BMS-986036 and the effects the drug has on the body

Timeline

Start
2017-06-28
Primary completion
2017-09-22
Completion
2017-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegbelfermin Protein / enzyme biologic — —

Indications

metabolic disease